Shenzhen, February 28 – Naleya Genomics Indonesia (NGI), a joint venture of BGI Group’s subsidiary, recently revealed its new clinical testing laboratory in Indonesia, which aims to enhance local precision medicine and public health development. During the opening ceremony, an MoU was signed between BGI Group and the Ministry of Health of Indonesia for cooperation in genomics studies, precision medicine development, and the Indonesian national gene bank. Budi Gunadi Sadikin, the Minister of Health of Indonesia, and Yin Ye, CEO of BGI Group, inaugurated the laboratory.
Budi Gunadi Sadikin, Minister of Health of Indonesia (fourth from right), Ayodhia G. Kalake, Secretary of the Coordinating Ministry of Maritime and Investment Affairs (second from right), and Yin Ye, CEO of BGI Group (third from right), jointly unveiled the laboratory.
Minister Budi congratulated the opening of the laboratory and recognized that Omics technology can improve reproductive health, prevent early-stage cancer and control infectious diseases, guide precise medication, and promote healthy lifestyles. The presence of BGI Group in the Indonesian market will further promote the development of precision medicine in Indonesia, making it more accessible to the Indonesian people. It will also enhance joint education programs as well as research development in Indonesia.
The new medical testing laboratory offers a range of localized pre-marital and pre-pregnancy testing services and serves as a training platform for local talent.
During the ceremony, an MoU was signed between BGI Group and the Indonesian Ministry of Health. The two parties will collaborate on genomics studies, precision medicine development, and the Indonesian national gene bank. Minister Budi expressed his hope that establishing a biological sample library system and improving the capability of sample storage and research will promote Indonesia's biological technology.
Budi Gunadi Sadikin, Minister of Health of Indonesia (left), and Yin Ye, CEO of BGI Group, witnessed the MoU signing between BGI Group and the Ministry of Health of Indonesia.
Yin Ye stated that BGI Group will work with Indonesia in the national gene bank, public health projects, and other areas, to continue contributing to Indonesia's life sciences, precision medicine, and biotechnology.
In 2022, the Indonesian Ministry of Health announced a six-pillar healthcare transformation strategy, with genomics being one of the key driving forces of the development of healthcare technology. In August, Indonesia's first "National Genome Program" was officially launched, with MGI becoming one of the designated sequencing platform partners, helping to establish an efficient, fully automated high-throughput sequencing technology platform. In November, Minister Budi met with Wang Jian, Co-Founder and Chairman of BGI Group, and his team. The two sides discussed the possibility of initiating collaboration in public health and the development of genomics, as well as improving the well-being of the Indonesian people by utilizing genomic technology.